Dyne Therapeutics (DYN) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 5, 2026, to be held virtually for stockholders of record as of April 7, 2026.

• Proxy materials, including the notice, proxy statement, and annual report, are available online, with paper copies available upon request.

Voting matters and shareholder proposals

• Election of three Class III directors for three-year terms expiring at the 2029 annual meeting.

• Advisory vote to approve named executive officer compensation.

• Proposal to amend the Restated Certificate of Incorporation to increase authorized common stock from 200,000,000 to 400,000,000 shares.

• Proposal to amend the Restated Certificate of Incorporation to provide for officer exculpation.

• Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.

Board of directors and corporate governance

• Board recommends voting FOR all five proposals, including director elections and amendments.